Please provide your email address to receive an email when new articles are posted on . Continuous cough monitoring allows for assessment of immediate treatment effects in patients with refractory ...

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of ...

Please provide your email address to receive an email when new articles are posted on . BMI was statistically significant for patients classified as having overweight, obesity or extreme obesity.

No one wants to be the person who can’t stop coughing. Not only is it uncomfortable on your throat, but it also draws angry stares from others in elevators, subway cars, and restaurants—especially ...

A survey of Scripps Health clinicians reveals that specialty and personal risk assessment of side effects drive the chronic cough treatment gap.

Chronic cough is a persistent and often debilitating condition defined as a cough lasting for more than eight weeks. This syndrome presents a significant clinical challenge worldwide due to its ...

Experts report that a chronic cough lasting at least 8 weeks disproportionately affects women, with prevalence increasing with age.

STATE COLLEGE, Pa. (WPVI) -- A cough is supposed to protect the lungs and windpipe from irritants. But coughs that go on and on can be annoying - or signs of bigger problems. Chronic coughs can have ...

CINCINNATI (WKRC) — If you're struggling with a chronic cough, it may be linked to several illnesses that are on the rise, according to public health providers. One significant concern is pertussis, ...

HONOLULU (KHON2) — A chronic cough can often times be a headache to deal with, especially if it interferes with your daily activities. Sometimes, it may be difficult to find out what’s causing it. Get ...

The FDA declined to approve oral gefapixant for treating chronic cough, Merck announced on Wednesday. In its complete response letter, "the FDA concluded that Merck's application did not meet ...